Gibson Dunn Advises Concentra Biosciences on Acquisition of CARGO Therapeutics, Inc.
Firm News | July 11, 2025
Gibson Dunn is representing Concentra Biosciences, an affiliate of Tang Capital Management, on its acquisition of CARGO Therapeutics, Inc. (Nasdaq: CRGX), a biotechnology company that has focused on developing CAR T-cell therapies.
Gibson Dunn regularly advises life sciences companies and investors on mergers and acquisitions in the biotechnology and cell therapy sectors.
The Gibson Dunn corporate team includes Ryan Murr and Evan Shepherd.